- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04784312
A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection
June 14, 2022 updated by: Mabwell (Shanghai) Bioscience Co., Ltd.
A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Immunogenicity of a Single Dose of MW14 Injection in Healthy Subjects
This is a Phase 1, first time in human study enrolling approximately 42 healthy adult subjects (18-45 yrs) from one study site.
The purpose of this study is to evaluate the safety, tolerability and PK of MW14 in healthy adult volunteers administered as a single IV dose compared with placebo, across 5 cohorts.
The 5 dose cohorts will enroll sequentially.
Subjects will be followed for safety from the time of Informed Consent through 85 days post dose.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200040
- HuaShan Hospital Fudan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects aged 18 to 45 years (including 18 and 45 years).
- Weight≥50.0 kg for males, or weight≥45.0 kg for females, and body mass index (BMI) in the range of 19.0 ~ 26.0 kg/m2 (including cut-off value).
- The medical history, physical examination, clinical laboratory tests and other tests related study show no abnormalities, or abnormalities without clinical significance.
- Subjects do not have a pregnancy plan, have no sperm and egg donation plans during the screening period and the next 6 months, and take effective contraceptive measures voluntarily.
- Are willing to follow study procedures, signed informed consent voluntarily, and ensure that he/she will complete the study according to the program requirements.
Exclusion Criteria:
Prior or current medical conditions:
- Health status: clinically significant histories of heart, liver, kidney, digestive tract, nervous system, respiratory system, blood and lymphatic system, immune system, mental, metabolic, and bone abnormalities.
- Subjects who have a history of allergies to biological agents or any drug components; those who have a history of allergies and judged by the investigator to be ineligible for enrollment.
- Those who undergone acute infection within 2 weeks prior to screening.
- Those with abnormalities in pulmonary imaging examination prior to screening and judged to be clinically significant by the investigator.
- Those who have undergone surgery within 3 months prior to screening, or who plan to undergo surgery during the study.
- Those who cannot tolerate venipuncture or have a history of needle-sickness and blood-sickness.
- Those who have a history of drug abuse within 6 months prior to screening.
- Use of illicit drugs within 3 months prior to screening.
- Those who donated blood within 3 months prior to screening (including component blood), or massive blood loss (≥ 200 mL), or blood transfusions or use of blood products.
- Subject (female) who is pregnant or lactating at screening or during the trial.
- Subjects have a fertility plan or sperm or egg donation plan at screening and within the next 6 months.
- Use of any prescription, over-the-counter, or Chinese herbal medicines within 2 weeks prior to screening.
- Those who have been vaccinated within 4 weeks prior to screening or who are scheduled to be vaccinated during the study.
- Those who have smoked more than 5 cigarettes per day within 3 months prior to screening.
- Those who have consumed more than 14 units of alcohol per week (1 unit of alcohol ≈ 360 mL of beer or 45 mL of spirits containing 40% alcohol or 150 mL of wine) within 3 months prior to screening, or who cannot abstain from alcohol during the trial.
- Those who have special dietary requirements and cannot accept a standard diet.
- Those who have participated in drug or medical devices clinical trials within 3 months prior to screening.
- Those who have previously used immunosuppressants or monoclonal antibodies for any reason.
- Those with abnormal vital signs with clinical significance: diastolic blood pressure≤50 mmHg or ≥90 mmHg, pulse≤50 beats/min or ≥100 beats/min, body temperature (ear temperature) <35.5°C or >37.5°C, respiration>20 breaths/min. The specific situation will be comprehensively determined by the investigator.
- Those with abnormalities in laboratory tests and auxiliary examinations that are judged by the investigator to be clinically significant.
- Those who have one or more clinically significant tests of hepatitis B virological markers, hepatitis C virus antibodies, anti-human immunodeficiency virus antibodies, or anti-Treponema pallidum-specific antibodies.
- Female subjects with a positive blood pregnancy test at screening.
- Alcohol breath test results greater than 0.0 mg/100 ml or positive drug screening (morphine, icenarcotics [methamphetamine], ketamine, ecstasy [methylenedioxyamphetamine], cannabis [tetrahydrocannabinolate], erythroxylin).
- Subjects who is inappropriate to participate in the trial due to any reasons as determined by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 9MW1411 injection
|
9MW1411 injection
|
Experimental: 9MW1411 injection placebo
|
9MW1411 injection placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Event
Time Frame: 12 weeks
|
safety evaluation
|
12 weeks
|
Serious Adverse Event
Time Frame: 12 weeks
|
safety evaluation
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 16, 2021
Primary Completion (Actual)
August 17, 2021
Study Completion (Actual)
August 17, 2021
Study Registration Dates
First Submitted
March 3, 2021
First Submitted That Met QC Criteria
March 3, 2021
First Posted (Actual)
March 5, 2021
Study Record Updates
Last Update Posted (Actual)
June 15, 2022
Last Update Submitted That Met QC Criteria
June 14, 2022
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9MW1411-2020-CP101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Staphylococcus Aureus Infection
-
Ohio State UniversityCompletedMethicillin-resistant Staphylococcus Aureus | Methicillin-Sensitive Staphylococcus Aureus InfectionUnited States
-
Washington University School of MedicineActive, not recruitingStaphylococcus Aureus | Skin and Subcutaneous Tissue Bacterial Infections | MRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
University of PennsylvaniaChildren's Hospital of Philadelphia; Milton S. Hershey Medical Center; Pennsylvania...CompletedMRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
Massachusetts General HospitalTerminatedMRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
Intron Biotechnology, Inc.CompletedHealthy Volunteers | Anti-Bacterial Agents | Methicillin-Resistant Staphylococcus Aureus | Methicillin-Sensitive Staphylococcus Aureus InfectionKorea, Republic of
-
University College, LondonKing's College London; Rambam Health Care Campus; University of Melbourne; Menzies... and other collaboratorsNot yet recruitingSepsis | Staphylococcus Aureus Infection | Bloodstream Infection | Staphylococcus Aureus Bacteremia | Sepsis Bacterial | Staphylococcus Aureus Septicemia | Staph Sepsis
-
CAMC Health SystemUnknownMRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
B. Braun Medical SATerminatedMRSA - Methicillin Resistant Staphylococcus Aureus Infection | MRSA ColonizationSpain
-
Menzies School of Health ResearchThe University of Queensland; Australasian Society for Infectious Diseases; Singapore... and other collaboratorsTerminatedMethicillin-Resistant Staphylococcus AureusAustralia, New Zealand, Israel, Singapore
-
R. Stephen Rankin, M.D.UnknownCommunity-acquired Methicillin-resistant Staphylococcus Aureus InfectionUnited States
Clinical Trials on 9MW1411 injection
-
Mabwell (Shanghai) Bioscience Co., Ltd.Recruiting
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Dalia Salah SaifUnknownRA - Rheumatoid ArthritisEgypt
-
Royan InstituteCompletedMyocardial InfarctionIran, Islamic Republic of
-
United States Naval Medical Center, San DiegoCEL-SCI CorporationTerminated